Evaluation of Comfilcon A and Senofilcon A Lenses

NCT ID: NCT01695369

Last Updated: 2020-07-28

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

61 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of Comfilcon A and Senofilcon A Lenses

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non-dispensing, single-masked, randomized, contralateral study comparing the test lens against the control lens. Each subject will be randomized to wear the test lens in one eye and the control lens in the other eye.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Senofilcon A

Senofilcon A; Comfilcon A

Group Type ACTIVE_COMPARATOR

Senofilcon A; Comfilcon A

Intervention Type DEVICE

Senofilcon A; Comfilcon A

Comfilcon A; Senofilcon A

Intervention Type DEVICE

Comfilcon A; Senofilcon A

Comfilcon A

Comfilcon A; Senofilcon A

Group Type EXPERIMENTAL

Senofilcon A; Comfilcon A

Intervention Type DEVICE

Senofilcon A; Comfilcon A

Comfilcon A; Senofilcon A

Intervention Type DEVICE

Comfilcon A; Senofilcon A

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Senofilcon A; Comfilcon A

Senofilcon A; Comfilcon A

Intervention Type DEVICE

Comfilcon A; Senofilcon A

Comfilcon A; Senofilcon A

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects must satisfy the following conditions prior to inclusion in the study:

* Has had an oculo-visual examination in the last two years
* Is at least 18 years of age and has full legal capacity to volunteer
* Has read and understood the information consent letter
* Is willing and able to follow instructions and maintain the appointment schedule
* Is correctable to a visual acuity of 20/30 or better (in each eye) with their habitual vision correction
* Currently wears soft contact lenses at least 3 days a week, 8 hours a day
* Has clear corneas and no active ocular disease
* Has not worn lenses for at least 12 hours before the examination
* Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:

* No amblyopia
* No evidence of lid abnormality or infection (e.g. entropion, ectropion, chalazia, recurrent styes)
* No clinically significant slit lamp findings (e.g. infiltrates or other slit lamp findings Grade 2 or above: corneal edema, tarsal abnormalities, and conjunctival injection).
* No other active ocular disease (e.g. glaucoma, history of recurrent corneal erosions, cornea \[infiltrates\], conjunctiva, lids, and intraocular infection or inflammation of an allergic, bacterial, or viral etiology)
* No aphakia
* Has prescription to match the available power range.

Exclusion Criteria

Any of the following will render a subject ineligible for inclusion:

* Greater than 0.75 of refractive astigmatism in either eye
* Has never worn contact lenses before
* Wears contact lenses on an extended wear basis
* Has any systemic disease affecting ocular health
* Is a known sufferer of ocular allergies
* Is taking medication, such as oral antihistamines, antihistamine eye drops, oral and ophthalmic beta-adrenergic blockers (e.g. Propanolol, Timolol), anticholinergics, oral steroids and any prescribed or over-the-counter eye medication, except artificial tears or eye lubricants
* Has any clinically significant lid or conjunctival abnormalities, neovascularization, corneal scars or corneal opacities
* Is aphakic
* Has undergone corneal refractive surgery.
* Is wearing monovision
* Is participating in any other type of clinical or research study
* Female who is currently pregnant or is breast-feeding
* Has \> grade 1 ocular corneal staining in both type and extent by \> grade 2 in either type or extent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CooperVision, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jan Bergmanson, OD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Houston College of Optometry, TERTC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Houston College of Optometry, TERTC

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CV-12-54

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.